Co-occurrence of Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Anti-myelin Oligodendrocyte Glycoprotein Inflammatory Demyelinating Diseases: A Clinical Phenomenon to Be Taken Seriously

Yijun Ren¹, Xiqian Chen¹, Qiang He¹, Renchun Wang² and Wei Lu*¹

¹ Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China, ² The Second Clinical Medicine School of Lanzhou University, Lanzhou, China

Background: Anti-N-methyl-D-aspartate receptor (NMDAR) immunoglobulin G antibodies which exist on myelin sheaths, composed of oligodendrocytes, especially target GluN1 subunits and are highly characteristic of anti-NMDAR encephalitis which is a newly recognized autoimmune encephalitis (AE) characterized by psychiatric symptoms, behavioral abnormalities, seizures, cognitive impairment and other clinical symptoms. Myelin oligodendrocyte glycoprotein (MOG) is a type of protein which is expressed on the surface of oligodendrocytes and myelin in the central nervous system. Anti-MOG antibodies cause demyelination. In some rare reported cases, these two types of antibodies have been found to co-exist, but the underlying mechanisms remain unknown.

Case presentation: Here we report cases of 4 inpatients (median age 31.5 years, age range 27–43 years) from The Second Xiangya Hospital of Central South University between March 2018 and April 2019. Two of the cases were first diagnosed as anti-NMDAR encephalitis and had developed visual impairments in the course of the dosage reduction during corticosteroid therapy. They were found at the time, to have anti-MOG antibody-positive CSF and/or serum. Another patient was diagnosed with anti-MOG inflammatory demyelinating diseases (IDDs) when he tested double positive for both anti-NMDAR and anti-MOG antibodies early in the course of his illness. Over the course of the dosage reduction during corticosteroid therapy, his symptoms deteriorated; however, anti-MOG antibody levels elevated while anti-NMDAR antibody levels remained low. The other patient had initially developed psychiatric symptoms and limb weakness. She was also double positive for anti-NMDAR and anti-MOG antibodies early in the course of her illness. However, over the course of the dosage reduction during corticosteroid therapy, her symptoms worsened and levels of both antibodies elevated.
INTRODUCTION

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe, but treatable autoimmune disorder with clinical manifestations of psychiatric and neurologic symptoms. It is often accompanied by a teratoma or other neoplasms, especially in female patients (1–6). Anti-NMDAR antibody-positive cerebrospinal fluid (CSF) or serum are characteristic, of the disease (5, 6). Myelin oligodendrocyte glycoprotein (MOG) is a type of protein which is expressed on the surface of oligodendrocytes and myelin in the central nervous system (CNS) (7). Antibodies to MOG can be detected in patients with inflammatory demyelinating diseases (IDDs) of the CNS (8). The international consensus is now that, anti-MOG antibodies result in demyelinating diseases, of the neuromyelitis optical spectrum disorders (NMOSD) (7, 9, 10). The pathogenic mechanisms of these two diseases were once believed to be entirely different, but several cases have recently reported the coexistence of anti-NMDAR and anti-MOG antibodies (3, 11–13). However, these consisted of individual cases or small sample reports, and no systematic review of large-scale samples has summarized, to date, the characteristic features of the coexistence of anti-NMDAR encephalitis and anti-MOG IDDs.

The purpose of this report is to discuss the possible mechanisms for the coexistence of multiple autoimmune antibodies, which leads to different autoimmune diseases, by comparing patients with partially similar clinical presentations.

MATERIALS AND METHODS

Patient Inclusion

This study was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University. In this retrospective observational study, we analyzed four inpatients between March 2018 and April 2019, who were either seropositive and/or CSF-positive for anti-NMDAR and anti-MOG antibodies. Patient 1 and 2 had symptoms typical of autoimmune encephalitis, including cephalalgia, speech disorder, and decreased consciousness, each of which meets the diagnostic criteria for anti-NMDAR encephalitis (see Table 1) (5). They were found to be anti-NMDAR antibody positive. Over the course of dosage reduction during corticosteroid treatment, these two patients developed visual impairments and were found to be anti-MOG antibody positive. Patient 3 developed dizziness, double vision, and weakness of the right limb but no visual impairment. He was found to be simultaneously anti-NMDAR and anti-MOG antibody-positive (Figures 2A,C). Based on the combination of clinical features and laboratory evidence, the patient was diagnosed with an anti-MOG inflammatory demyelinating disease, though the anti-NMDAR antibody titer was too low to establish a definitive diagnosis of anti-NMDAR encephalitis. Over the course of his immunosuppressive treatment, he developed visual impairment and his anti-MOG antibody titer increased (Figures 2D,E) (his anti-NDMAR antibody titer remained low simultaneously, Figure 2B). Patient 4 first developed cephalalgia, psychiatric symptoms, weakness and numbness of the limbs early in the course of her illness. She was found, at that time, to be double positive for anti-NMDAR and anti-MOG antibodies in the CSF and serum. Considering the clinical symptoms, laboratory findings and imaging findings, she was diagnosed with anti-MOG-positive NMOSD with low titer of anti-NMDAR antibodies. She also developed visual impairments over the course of dosage reduction during corticosteroid therapy, accompanied with increase in the anti-NMDAR and anti-MOG antibody titers. She was finally diagnosed with anti-MOG-positive NMOSD and anti-NMDAR encephalitis.

All of the four patient were seronegative and CSF-negative for anti-GABABR, anti-AMPA1, anti-AMPA2, anti-CASPR2, anti-LG11, anti-AQP-4, and anti-MOG. Antibodies testing were done through cell-based assays (BCA) in the Guangzhou King Med Center for Clinical Laboratory. Following the guidelines of Guangzhou King Med Center for Clinical Laboratory, the antibody cut-off level was 1:32, and full-length human antigenic substrates were used.

RESULTS

Here we describe the cases of four inpatients at the Second Xiangya Hospital of Central South University between March 2018 and April 2019, who were either seropositive and/or CSF-positive for anti-NMDAR and anti-MOG antibodies. The antibodies panel included anti-NMDAR, anti-GABABR, anti-AMPA1, anti-AMPA2, anti-CASPR2, anti-LG11, anti-AQP-4, and anti-MOG. The antibodies panel included anti-NMDAR, anti-GABABR, anti-AMPA1, anti-AMPA2, anti-CASPR2, anti-LG11, anti-AQP-4, and anti-MOG. Antibodies testing were done through cell-based assays (BCA) in the Guangzhou King Med Center for Clinical Laboratory. Following the guidelines of Guangzhou King Med Center for Clinical Laboratory, the antibody cut-off level was 1:32, and full-length human antigenic substrates were used.

Conclusion: Anti-NMDAR and anti-MOG antibodies may coexist in rare cases. In addition, anti-NMDAR encephalitis and anti-MOG inflammatory demyelinating diseases may occur either simultaneously or in succession. Thus, when a patient is diagnosed with either of these two diseases, but exhibits symptoms of the other disease, the possibility of co-occurrence with both these diseases should be considered and the appropriate treatments should be accurately detected to enable prompt selection of appropriate treatments by the physicians.

Keywords: autoimmune encephalitis, N-methyl-D-aspartate (NMDA), demyelinating diseases, myelin oligodendrocyte glycoprotein (MOG), immunotherapy
**TABLE 1** | Clinical characteristic laboratory data and treatments of cases in first and relapse episode.

| Characteristic                        | Patient 1                                      | Patient 2                                      | Patient 3                                      | Patient 4                                      |
|--------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Initial Symptoms                     | Alalia, cephalalgia, numbness of right upper limb | Weakness and numbness of left upper limb, disturbance of consciousness | Dizziness, double vision, weakness of right limb | Cephalalgia, psychiatric symptoms, weakness, and numbness of limbs |
| **LABORATORY DATA OF INITIAL EPISODE** |                                                |                                                |                                                |                                                |
| CSF Findings                         | CSF P, mmH2O                                   | 190                                            | 280                                            | 170                                            | 150                                            |
|                                      | CSF WBC (10^3/L)                               | 8                                              | 240                                            | 30                                             | 88                                             |
|                                      | CSF protein (mg/dL)                            | 166.4                                          | 250.6                                          | 293.3                                          | 444.52                                         |
|                                      | CSF/serum anti-NMDAR-ab                        | 1:32 pos/1:10 pos                              | 1:32 pos/1:10 pos                              | 1:10 pos/Na                                    | 1:10 pos/Na                                    |
| Other Findings                       | CSF/serum antibodies to AMPA1, AMPAR2, CASPR2, LGI1, GABAR | Neg                                           | Neg                                           | Neg                                            | Neg                                            |
| Imaging findings of initial episode  | MRI revealed lesions that were high signal on T1WI and T2WI in callosal and around the ventricle (Figure 1C) | Abnormal swelling of the left hippocampus with high signal in T2/flair (Figure 1A) | High signal on T1WI/T2WI in midbrain, high signal on T2 fat-suppression sequence in C7-T1/T7-T12 spinal cord plane | High signal on T1WI/T2WI in right pons and aqueduct of sylvius, Spinal cord lesions are as mentioned before |
| Treatments with immunosuppressant    | High-dose intravenous corticosteroids, orally corticosteroids treatment (initial 60 mg/d and decreased 5 mg every 2 weeks) | IVIG, High-dose intravenous corticosteroids, natalizumab infusions (600 mg), MMF | High-dose intravenous corticosteroids, orally corticosteroids treatment (initial 60 mg/d and decreased 5 mg every 2 weeks), MMF | High-dose intravenous corticosteroids, orally corticosteroids treatment (initial 60 mg/d and decreased 5 mg every 2 weeks), AZA |
| Time since symptoms relieved to elapse episode, mo | 7                                              | 0.5                                            | 12                                             | 6                                              |
| Dosage of immunosuppressors          | Drug withdrawal                                | MMF (600 mg/d)                                 | Irregularly medication                          | Corticosteroids(30 mg/d), AZA(100 mg/d)         |
| Relapse symptoms                     | Blurred vision in right eye                    | Acute and progressive diminution of vision     | Dizziness, blurred vision                      | Blurred vision, diplopia                        |
| **LABORATORY DATA OF RELAPSE EPISODE** |                                                |                                                |                                                |                                                |
| CSF Findings                         | CSF P, mmH2O                                   | 140                                            | 200                                            | 190                                            | 140                                            |
|                                      | CSF WBC (10^3/L)                               | 8                                              | 4                                              | 4                                              | 4                                              |
|                                      | CSF protein (mg/dL)                            | 235.1                                          | 321.8                                          | 166.87                                         | 373.18                                         |
|                                      | CSF/serum anti-NMDAR-ab                        | 1:32 pos/1:32 pos                              | 1:32 pos/1:32 pos                              | 1:10 pos/Na                                    | 1:32 pos/1:10 pos                              |
| Other Findings                       | CSF/serum anti-MOG-ab                          | 1:10 pos/Na                                    | 1:10 pos/Na                                    | 1:100 pos/1:32 pos                             | 1:100 pos/1:10 pos                             |
| Imaging findings of relapse episode  | MRI revealed lesions that were high signal on T1WI and T2WI in centrum semiovale; enlargement of the left optical nerve (Figure 1D) | High signal on T1WI and T2WI in posterior horn of lateral ventricle and right cerebellar hemisphere (Figure 1F) | New high signal lesions on T1WI/T2WI in right pons and aqueduct of sylvius, Spinal cord lesions are as mentioned before | High-dose intravenous corticosteroids, orally corticosteroids treatment (initial 60 mg/d and decreased 5 mg every 2 weeks), AZA(150 mg/d) |
| Treatment of relapse episode         | Treatment refusal                              | orally corticosteroids treatment               | Orally corticosteroids treatment, AZA         | Orally corticosteroids treatment (initial 60 mg/d and decreased 5 mg every 2 weeks), AZA(150 mg/d) |

MOG, myelin oligodendrocyte glycoprotein; AQP4, aquaporin 4; NMDAR, N-methyl-D-aspartate receptor; CASPR2, contactin associated protein 2; LGI1, leucine-rich glioma-inactivated 1; AMPAR, anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; GABAR, anti-gamma-aminobutyric acid receptor; CSF, cerebrospinal fluid; IVIG, intravenous immunoglobulin; AZA, azathioprine; MMF, mycophenolate mofetil; WBC, white blood cell; TPO-ab, thyroid peroxidase antibody; Neg, negative; pos, positive; Na, not applicable.

Supplementary Table MOG-IgG cut-off 1:32; assay: CBA, Guangzhou King Med Center for Clinical Laboratory; antigen: full-length human MOG (14).

to cause autoimmune encephalitis (4, 5). In addition, they were also anti-AQP-4 antibody-negative in serum and CSF. Detailed clinical information is summarized in the Table 1.
total suppression of immunosuppressant therapy, all the patients developed visual impairments, thereby, needing hospitalization again. On assessment, anti-MOG and anti-NMDAR antibody titers in the CSF and/or serum showed altered levels.

Two of the 4 patients were male, with a median onset age of 31.5 years (age range 27–43 years). The median time from initial symptoms until the onset of visual impairment was 6.5 months (range 0.5–12 months). Patients 1, 3, and 4 developed visual impairments on dosage reduction (or withdrawal) of corticosteroids, and patient 2 additionally received a Mycophenolate Mofetil treatment.

DISCUSSION

Anti-NMDAR encephalitis has recently been clinically recognized, and is reported to be associated with the presence of specific CSF IgG antibodies to NMDA receptors, especially against GluN1 subunits (4). Anti-NMDAR encephalitis commonly causes psychiatric symptoms, behavioral abnormalities, seizures, speech disorder, cognitive impairment and decreased consciousness (1, 2, 4–6). It has also been reported to sometimes co-occur with a teratoma, especially in female patients, or an intracranial viral infection (15). Neuromyelitis optical (NMO) was once believed to be associated with the presence of autoantibodies to aquaporin-4 (AQP-4) (16). However, further research revealed that 10–20% of patients with NMO were negative for AQP4-IgG but positive for MOG antibodies (8, 9, 17). MOG-IgG-related NMO is now widely recognized as a specific disease (10). In a cohort study of 50 patients, the sex ratio was found to be 1:2.8 (M:F) and the median age was 31 years (age range 6–70 years) (8). These data are characteristic to severe visual impairment or functional blindness, and markedly impaired ambulation. Responses to intravenous methylprednisolone and long-term immunosuppression treatment were satisfactory (2, 4, 6, 8, 17, 18).

The coexistence of MOG and NMDAR antibodies has so far only rarely been reported. Titulaer et al. (3) conducted a retrospective analysis of 691 cases of anti-NMDAR encephalitis, including 23 patients who were diagnosed with anti-NMDAR encephalitis with comorbid symptoms of demyelination. Among them, nine patients had anti-MOG antibodies with similar serological findings to the four cases described in this report. Zhou et al. (12) reported the case of a 31 year-old man whose initial symptoms were fever, headache and seizures, alongside numbness, neuritis and unsteady walking during subsequent episodes. In this case, both anti-NMDAR and anti-MOG antibodies were simultaneously detected, however, researchers believe that the diagnosis of MOG-IDD is definite, while that of AE remains controversial. This is due to the fact that, according to them, NMDAR antibodies were not present...
Simultaneously, anti-NMDAR encephalitis and anti-MOG IDDs could also occur. The clinical course of two of these cases matched previous reports (12, 19, 20). However, the rate of co-occurrence of autoimmune encephalitis and a demyelinating disease remains unclear, to date (3). Secondly, multiple seropositivity may also be attributed to immune reconstitution. It is widely known that different types of immunotherapies (including corticosteroid treatment) may influence immunological status. On dosage reduction or withdrawal of immunotherapy, the immune system will recover from immunosuppression (21) and rebuild itself; thus causing immune cells to attack autoantigens and lead to inflammatory CNS responses (22–24). Some researchers have found that AIDS patients who are immunodeficient may relapse or develop other complications during the course of combination antiretroviral therapy (25, 26). This is termed immune reconstitution inflammatory syndrome (IRIS). Researchers have attributed IRIS to immune reconstitution (i.e., changes in CD4+ T cell counts) (21, 23). Similarly, relapses and new clinical syndromes caused by new-onset autoimmune antibodies or increase in the titers, thereof, could result during dosage reduction or withdrawal of corticosteroid therapy.

Thus, we insist that anti-NMDAR and anti-MOG antibodies can exist simultaneously, sometimes even when the initial symptoms of patients are primarily caused by one of these two antibodies. Regardless of whether a patient first presents with clinical symptoms of anti-NMDAR encephalitis or anti-MOG IDDs, if a patient develops new impairments during the course of immunity-regulating therapies, the potential co-occurrence of these two types of diseases must be considered. If a patient is found double positive for these two types of antibodies, especially when new symptoms develop during immunotherapeutic treatment, the immunomodulatory therapy protocols should be expeditiously developed, and the most suitable treatment protocols should be carefully selected in advance.

**CONCLUSIONS**

We believe that anti-MOG and anti-NMDAR antibodies may coexist either simultaneously or in succession. As such, anti-NMDAR encephalitis and anti-MOG IDDs could occur simultaneously or successively. Therefore, neurologists should pay close attention to these conditions and choose appropriate treatment strategies.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/supplementary material.
REFERENCES

1. Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. (2012) 83:638–45. doi: 10.1136/jnnp-2011-301237

2. Glaser C, Izuoka T, Honig LS, Aguilar E, Gresa-arribas N, Ryan-florance N. Encephalitis: a cohort study. Lancet Neurol. (2014) 12:157–65. doi:10.1016/S1474-4422(12)70310-1

3. Titulaer MJ, Höfberger R, Izuoka T, Leyboldt F, McCracken L, Cellucci T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. (2014) 75:411–28. doi: 10.1002/ana.24117

4. Leyboldt F, Armanque T, Dalmau J, Autoimmune encephalopathies. Ann N Y Acad Sci. (2015) 1338:94–114. doi:10.1111/nyas.12553

5. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. (2016) 15:391–404. doi: 10.1016/S1474-4422(15)00401-9

6. Zhang L, Wu MQ, Hao ZL, Chiang SMV, Shuang K, Lin MT, et al. Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis: a systematic review of reported cases. Epilepsy Behav. (2017) 88:57–65. doi:10.1016/j.yebeh.2016.12.019

7. Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:307–24. doi: 10.1016/j.autrev.2015.12.004

8. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

9. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

10. Byrne S, Walsh C, Hacohen Y, Muscal E, Jankovic J, Stocco A, et al. Earlier treatment of nmdar antibody encephalitis in children results in a better outcome. Neurology. (2016) 50:7–9. doi: 10.1212/01.wnl.0000499540.000130

11. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

12. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

13. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

14. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

15. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

16. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

17. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

18. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

19. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

20. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

21. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

22. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. (2016) 15:391–404. doi: 10.1016/j.autrev.2015.12.004

ACKNOWLEDGMENTS

This is a short text to acknowledge the contributions of WL and my schoolfellows that aided the efforts of the authors. They generously helped me collect materials I needed and made many invaluable suggestions.
24. Van Obberghen EK, Cohen M, Rocher F, Lebrun-Frenay C. Multiple immune disorders after natalizumab discontinuation: after the CIRIS, the SIRIS? Rev Neurol. (2017) 173:222–4. doi: 10.1016/j.neurol.2017.03.008

25. Johnson TP, Nath A. New insights into immune reconstitution inflammatory syndrome of the central nervous system. Curr Opin HIV AIDS. (2014) 9:572–8. doi: 10.1097/COH.0000000000000107

26. Van Bilsen WPH, Van Den Berg CHSB, Rijnders BJA, Brinkman K, Mulder JW, Gelinck LBS, et al. Immune reconstitution inflammatory syndrome associated with toxoplasmic encephalitis in HIV-infected patients. AIDS. (2017) 31:1415–24. doi: 10.1097/QAD.0000000000001492

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Ren, Chen, He, Wang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.